Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

Pharmaceutical Targeting the Envelope Protein of SARS-CoV-2: the Screening for Inhibitors in Approved Drugs

14 May 2020, Version 1
Working Paper
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

An essential overview of the biological role of coronavirus viroporin (envelope protein) is given, together with the effect of its known inhibitors on the life cycle of coronavirus. A docking study is conducted using a set of known drugs approved worldwide (ca. 6000 compounds) on a structure of the SARS-CoV-2 viroporin modelled from the published NMR-resolved structures. The screening has identified 36 promising drugs currently on the market, which could be proposed for pre-clinical trials.

Keywords

SARS-CoV-2
E protein
viroporin
repurposing
docking

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Version History

May 14, 2020 Version 1

Metrics

5,891
2,243
5
Views
Downloads

License

CC logo
CC
BY logo
BY
The content is available under CC BY 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv.12286421.v1
D O I: 10.26434/chemrxiv.12286421.v1 [opens in a new tab]

Author’s competing interest statement

I have no conflict of interests.

Share